In the last trading session, 1.2 million Nurix Therapeutics Inc (NASDAQ:NRIX) shares changed hands as the company’s beta touched 2.14. With the company’s per share price at $18.60 changed hands at -$0.41 or -2.16% during last session, the market valuation stood at $1.32B. NRIX’s last price was a discount, traded about -58.92% off its 52-week high of $29.56. The share price had its 52-week low at $7.65, which suggests the last value was 58.87% up since then. When we look at Nurix Therapeutics Inc’s average trading volume, we note the 10-day average is 0.69 million shares, with the 3-month average coming to 908.08K.

Analysts gave the Nurix Therapeutics Inc (NRIX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended NRIX as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight. Nurix Therapeutics Inc’s EPS for the current quarter is expected to be -0.67.

Nurix Therapeutics Inc (NASDAQ:NRIX) trade information

Instantly NRIX was in red as seen at the end of in last trading. With action -3.23%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -1.27%, with the 5-day performance at -3.23% in the red. However, in the 30-day time frame, Nurix Therapeutics Inc (NASDAQ:NRIX) is -12.72% down. Looking at the short shares, we see there were 10.79 million shares sold at short interest cover period of 11.73 days.

The consensus price target for the stock as assigned by Wall Street analysts is 34.5, meaning bulls need an upside of 46.09% from its current market value. According to analyst projections, NRIX’s forecast low is 26 with 41 as the target high. To hit the forecast high, the stock’s price needs a -120.43% plunge from its current level, while the stock would need to soar -39.78% for it to hit the projected low.

Nurix Therapeutics Inc (NRIX) estimates and forecasts

Data shows that the Nurix Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -17.99% over the past 6 months, a -6.04% in annual growth rate that is considerably lower than the industry average of 16.70%. Year-over-year growth is forecast to reach -29.01% down from the last financial year.

Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 12.88M. 7 analysts are of the opinion that Nurix Therapeutics Inc’s revenue for the current quarter will be 14.78M. The company’s revenue for the corresponding quarters a year ago was 15.16M and 16.59M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -15.06%. The estimates for the next quarter sales put growth at -10.90%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -59.00%. The 2025 estimates are for Nurix Therapeutics Inc earnings to decrease by -6.03%.

NRIX Dividends

Nurix Therapeutics Inc is expected to release its next quarterly earnings report in February.

Nurix Therapeutics Inc (NASDAQ:NRIX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.45% of Nurix Therapeutics Inc shares while 97.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.22%. There are 97.78% institutions holding the Nurix Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 12.4218% of the shares, roughly 6.82 million NRIX shares worth $142.33 million.

REDMILE GROUP, LLC holds the second largest percentage of outstanding shares, with 8.0571% or 4.42 million shares worth $92.32 million as of 2024-06-30.

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.13 shares estimated at $39.59 million under it, the former controlled 3.00% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.32% of the shares, roughly 1.64 shares worth around $30.55 million.